Synthonics is a specialty pharmaceutical company that utilizes its proprietary metal coordination chemistry to create new, patentable metal coordinated pharmaceuticals (“MCPs”) that are safer, more stable, and more efficacious than their congeners.

Metal coordination imparts superior pharmacodynamic properties that result in greater and more consistent bioavailability of the active agent. By scaffolding other biologically active agents within their structure, MCPs can also uniquely facilitate targeted and synergistic delivery of drugs to specific organ systems.

MCPs represent a new generation of pharmaceuticals.  Metal coordination can be used to create innovative and distinct versions of existing or patent-expiring pharmaceuticals, and could be profitably applied to once promising drug candidates that had been abandoned due to issues regarding safety, instability, efficacy, or problems with drug delivery.